Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Adding another player to the immuno-oncology arena, Akrevia Therapeutics has launched with $30 million in its first formal round of financing from F-Prime Capital Partners and Atlas Venture. Founded on technology from cancer hospital City of Hope and Thomas Jefferson University, Akrevia is developing antibodies, cytokines, and chemokines that are activated only in the vicinity of the tumor. By rendering potent molecules inactive until they reach the tumor microenvironment, Akrevia hopes to enable the use of signaling proteins that are otherwise limited because of their toxicity.
This article has been sent to the following recipient: